EyeBio

eyebiotech.com

Eye Bio is a clinical-stage ophthalmology biotech company focused on developing innovative therapies to protect, restore, and improve vision for patients with eye diseases. The company was co-founded by leaders in the field who previously introduced the first anti-VEGF therapy for age-related macular degeneration. With a strong backing from prominent healthcare investors, Eye Bio is building a diverse pipeline of advanced therapies, including its lead asset Restoret, which targets the Wnt pathway for retinal diseases. The company's experienced leadership and commitment to innovation position it well in the ophthalmology market, aiming to redefine treatment standards for eye diseases.